Actively Recruiting
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
Led by Gustave Roussy, Cancer Campus, Grand Paris · Updated on 2025-02-07
50
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
CONDITIONS
Official Title
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of diffuse large B-cell lymphoma or follicular lymphoma needing first line treatment with RCHOP 21 regimen
- Agreement to participate after receiving oral and written study information
You will not qualify if you...
- Previous lymphoma treatment (except localized low dose radiotherapy for follicular lymphoma)
- Treatment using a chemotherapy regimen other than RCHOP 21
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
Research Team
D
David GHEZ
CONTACT
C
Christophe MARZAC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here